Highlights ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
8.12 ^USD	+0.74%		-11.26%	+61.75%

05-09	ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	05-07	MT
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	05-07	CI
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	05-02	CI
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	04-25	CI
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	04-23	MT
US FDA approves ImmunityBio's bladder cancer therapy	04-22	RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	04-22	CI
U.S. FDA approves ImmunityBio's bladder cancer therapy	04-22	RE
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
ImmunityBio Announces Data from A Phase 1 Pilot Study	03-05	CI
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	02-21	CI
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	02-05	CI
Top Stories at Midday: US Construction Spending Up 0.4% in November; Avangrid-PNM Resources Deal Terminated; Terreno Realty Sells California Property for $15.9 Million; ImmunityBio Secures $320 Million Investment	01-02	MT
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity	11-07	CI
ImmunityBio Shares Rise After FDA Accepted Resubmitted Biologics License Application for N-803 Plus BCG	23-10-26	MT
ImmunityBio Says FDA Accepted Resubmitted Biologics License Application for N-803 Plus BCG	23-10-26	MT
ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date	23-10-26	CI
ImmunityBio Resubmits Biologics License Application for Bladder Cancer Combination Therapy	23-10-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Highlights

Filters